Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy...

Por Hesketh, P. J., Rossi, G., Rizzi, G., Palmas, M., Alyasova, A., Bondarenko, I., Lisyanskaya, A., Gralla, R. J.
Publicado em 2014

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

Por Chow, L W-C, Xu, B, Gupta, S, Freyman, A, Zhao, Y, Abbas, R, Vo Van, M-L, Bondarenko, I
Publicado em 2013

A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

Por Eisen, T, Loembé, A-B, Shparyk, Y, MacLeod, N, Jones, R J, Mazurkiewicz, M, Temple, G, Dressler, H, Bondarenko, I
Publicado no Br J Cancer (2015)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and...

Por Aapro, M., Rugo, H., Rossi, G., Rizzi, G., Borroni, M. E., Bondarenko, I., Sarosiek, T., Oprean, C., Cardona-Huerta, S., Lorusso, V., Karthaus, M., Schwartzberg, L., Grunberg, S.
Publicado em 2014

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer(†)

Por O'Shaughnessy, J., Campone, M., Brain, E., Neven, P., Hayes, D., Bondarenko, I., Griffin, T. W., Martin, J., De Porre, P., Kheoh, T., Yu, M. K., Peng, W., Johnston, S.
Publicado no Ann Oncol (2016)